Hepatitis C
📧 Sign up to get email alerts when something new happens for Hepatitis C.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2012-04-23Clinical Trial Update: Rate and Predictors of Relapse in the Treatment of Hepatitis C (Study P05181)
This clinical trial update reports the rate of relapse and predictors of relapse in the treatment of chronic hepatitis C in study P05181; re…
-
CLINICAL_TRIALS trial_result · 2012-04-23Clinical Trial Update: Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Participants With/Without Substitution Therapy (P05255)
This ClinicalTrials.gov update reports results from a completed study evaluating treatment of chronic hepatitis C with pegylated interferon …
-
CLINICAL_TRIALS trial_result · 2012-04-20Clinical Trial Update: PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR) [Phase 4]
Phase 4 trial evaluating 16- or 24-week pegylated interferon alfa-2a plus ribavirin in adults with chronic hepatitis C genotype 2 who have a…
-
CLINICAL_TRIALS trial_result · 2012-04-18Clinical Trial Update: Comparison of Safety and Resulting Blood Level Profiles After Administration of a New Boceprevir Tablet Versus Its Current Capsule Formulation for Treatment of Chronic Hepatitis C (P06992)(COMPLETED) [Phase 1]
Phase 1 study comparing the safety and blood concentration profiles of a new Boceprevir tablet versus the current capsule formulation for ch…
-
CLINICAL_TRIALS trial_result · 2012-04-10Clinical Trial Update: Study of CTS-1027 in Combination With Pegylated Interferon and Ribavirin in Hepatitis C Virus (HCV) Null-Responders [Phase 2]
Completion of a Phase 2 study evaluating CTS-1027 with pegylated interferon and ribavirin in hepatitis C virus null-responders, with results…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2012-04-06Clinical Trial Update: Coffee Effect in HCV-related Hepatitis [Phase 3]
Phase 3 trial evaluating the effect of coffee in chronic hepatitis C has completed.
-
CLINICAL_TRIALS trial_result · 2012-04-03Clinical Trial Update: Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis [Phase 2]
This update summarizes a Phase 2 trial evaluating rituximab for hepatitis C–associated cryoglobulinemic vasculitis. The study has completed …
-
CLINICAL_TRIALS trial_result · 2012-03-27Clinical Trial Update: CTS-1027 in Interferon-Naive Hepatitis C Patients [Phase 2]
Phase 2 trial of CTS-1027 in interferon-naive hepatitis C patients has been completed, with results posted in 2012.
-
CLINICAL_TRIALS trial_result · 2012-03-26Clinical Trial Update: A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection [Phase 1]
Phase 1 study evaluating safety, tolerability, pharmacokinetics, and antiviral activity of GS-6620 in treatment-naïve subjects with chronic …
-
CLINICAL_TRIALS withdrawal · 2012-03-19Clinical Trial Update: 24 VS 48-WEEK TREATMENT WITH PEG-IFN ALPHA-2A IN PATIENTS WITH GENOTYPE 2/3 CHRONIC HEPATITIS C [Phase 3]
A Phase 3 trial evaluating 24- versus 48-week pegylated interferon alfa-2a therapy for genotype 2/3 chronic hepatitis C was withdrawn.
-
CLINICAL_TRIALS trial_result · 2012-03-13Clinical Trial Update: High Dose Versus Standard Dose of Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 [Phase 4]
This Phase 4 trial compares high-dose versus standard-dose ribavirin in patients with chronic hepatitis C genotype 3. The study has complete…
-
CLINICAL_TRIALS trial_result · 2012-03-08Clinical Trial Update: Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCV
This clinical trial extension reports long-term follow-up for subjects with chronic hepatitis C who elected retreatment with pegylated inter…
-
CLINICAL_TRIALS trial_result · 2012-03-06Clinical Trial Update: Efficacy of Peginterferon Alfa-2b (SCH 054031) vs Glycyrrhizin in Interferon (IFN)-Treated Patients With Chronic Hepatitis C and F2/F3 Liver Fibrosis (P04773) [Phase 3]
Phase 3 trial comparing peginterferon alfa-2b to glycyrrhizin in interferon-treated patients with chronic hepatitis C and F2/F3 liver fibros…
-
CLINICAL_TRIALS trial_result · 2012-03-02Clinical Trial Update: Switch From Tacrolimus to Cyclosporin in the Treatment of Recurrent Hepatitis C After Liver Transplantation [Phase 3]
Phase 3 trial evaluating switching from tacrolimus to cyclosporin for recurrent hepatitis C after liver transplantation was terminated.
-
CLINICAL_TRIALS trial_result · 2012-02-22Clinical Trial Update: Efficacy of Pegylated Interferon on Liver Fibrosis in Co-infected Patient With HIV and Hepatitis C [Phase 3]
Phase 3 trial evaluating pegylated interferon for liver fibrosis in patients co-infected with HIV and hepatitis C; the study is completed.
-
CLINICAL_TRIALS trial_result · 2012-02-17Clinical Trial Update: Legalon SIL for the Treatment of HCV Recurrence in Liver Transplanted Patients [Phase 2]
Phase 2 trial of Legalon SIL (silibinin) for treatment of hepatitis C recurrence after liver transplantation was terminated.
-
CLINICAL_TRIALS trial_result · 2012-02-14Clinical Trial Update: The Effects of Mogroside Sweetener on Viral Load in TreatmenT Naive Genotype 1 (GT 1) Subjects CHC [Phase 2]
A Phase 2 clinical trial assessing the effect of mogroside sweetener on hepatitis C viral load in treatment-naive genotype 1 patients has co…
-
CLINICAL_TRIALS trial_result · 2012-02-14Clinical Trial Update: Efficacy of Actos Lipitor Pegasys & Ribavirin in CHC GT 1 Patients Who Relapsed or Nonresponded to Peg/Riba [Phase 4]
Phase 4 clinical trial evaluating the efficacy of a quadruple regimen (pioglitazone, atorvastatin, pegylated interferon alfa-2a, and ribavir…
-
CLINICAL_TRIALS trial_result · 2012-02-14Clinical Trial Update: Pioglitazone on Viral Kinetics, Cytokines and Innate Immunity in Insulin Resistant CHC GT 1 Subjects [NA]
A completed clinical trial evaluating the effect of pioglitazone on viral kinetics, cytokines, and innate immunity in insulin-resistant indi…
-
CLINICAL_TRIALS trial_result · 2012-02-14Clinical Trial Update: Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC [Phase 4]
Phase 4 clinical trial update evaluating induction with PEG-Intron plus Rebetol to potentially improve sustained virologic response in patie…
-
CLINICAL_TRIALS trial_result · 2012-02-14Clinical Trial Update: Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus [Phase 4]
Phase 4 clinical trial evaluating initial treatment of significant fatty liver with Xenical (orlistat) followed by Hepatitis C therapy with …
-
CLINICAL_TRIALS trial_result · 2012-02-14Clinical Trial Update: Infergen, Ribavirin & Avandia in Previous Relapsers or Nonresponders to Pegylated Interferon and Ribavirin [Phase 4]
Phase 4 trial evaluating Infergen (interferon alfacon-1) plus ribavirin and Avandia (rosiglitazone) in hepatitis C patients who previously r…
-
CLINICAL_TRIALS trial_result · 2012-02-06Clinical Trial Update: Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic HepC Virus Genotype 1 Infection [Phase 1, Phase 2]
Update on a completed Phase 1/2 clinical trial evaluating Bavituximab in combination with Ribavirin as initial treatment for chronic hepatit…
-
CLINICAL_TRIALS trial_result · 2012-02-03Clinical Trial Update: Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C [Phase 1, Phase 2]
This document reports a completed Phase 1/2 trial comparing the safety, tolerability, and antiviral effects of Locteron to PEG-Intron in pat…
-
CLINICAL_TRIALS withdrawal · 2012-02-03Clinical Trial Update: Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C [Phase 3]
Phase 3 trial comparing pegylated interferon lambda to pegylated interferon alfa plus ribavirin for hepatitis C was withdrawn.